DNA methylation-dependent silencing of CST6 in human breast cancer cell lines - PubMed (original) (raw)
. 2006 Dec;86(12):1233-42.
doi: 10.1038/labinvest.3700485. Epub 2006 Oct 16.
Affiliations
- PMID: 17043665
- DOI: 10.1038/labinvest.3700485
Free article
DNA methylation-dependent silencing of CST6 in human breast cancer cell lines
Ashley G Rivenbark et al. Lab Invest. 2006 Dec.
Free article
Abstract
Cystatin M (CST6) is a candidate breast cancer tumor suppressor that is expressed in normal and premalignant breast epithelium, but not in metastatic breast cancer cell lines. CST6 is subject to epigenetic silencing in MCF-7 breast cancer cells related to methylation of the CpG island that encompasses the CST6 proximal promoter region and exon 1. In the current study, CST6 CpG island methylation and expression status was examined in a panel of breast cancer cell lines. Seven of 12 (58%) cell lines lack detectable expression of CST6 and treatment of these cells with 5-aza-2'-deoxycytidine resulted in a significant increase in CST6 expression, suggesting that the loss of expression may be related to methylation-dependent epigenetic silencing. Bisulfite sequencing of CST6 in a subset of breast cancer cell lines revealed CpG island hypermethylation in CST6-negative cells, and an absence of CpG island methylation in cells that express CST6. The extent of regional methylation was strongly associated with the lack of expression of CST6 among these cell lines. In particular, hypermethylation of the proximal promoter was significantly associated with CST6 gene silencing, and methylation of a number of individual CpGs was found to be statistically correlated with extinction of gene expression. These results establish a strong link between CST6 promoter hypermethylation and loss of CST6 expression in breast cancer cell lines, and suggest that methylation-dependent epigenetic silencing of CST6 may represent an important mechanism for loss of CST6 during breast carcinogenesis in vivo.
Similar articles
- DNMT3b overexpression contributes to a hypermethylator phenotype in human breast cancer cell lines.
Roll JD, Rivenbark AG, Jones WD, Coleman WB. Roll JD, et al. Mol Cancer. 2008 Jan 25;7:15. doi: 10.1186/1476-4598-7-15. Mol Cancer. 2008. PMID: 18221536 Free PMC article. - Methylation-dependent silencing of CST6 in primary human breast tumors and metastatic lesions.
Rivenbark AG, Livasy CA, Boyd CE, Keppler D, Coleman WB. Rivenbark AG, et al. Exp Mol Pathol. 2007 Oct;83(2):188-97. doi: 10.1016/j.yexmp.2007.03.008. Epub 2007 Apr 18. Exp Mol Pathol. 2007. PMID: 17540367 Free PMC article. - Aberrant methylation and silencing of ARHI, an imprinted tumor suppressor gene in which the function is lost in breast cancers.
Yuan J, Luo RZ, Fujii S, Wang L, Hu W, Andreeff M, Pan Y, Kadota M, Oshimura M, Sahin AA, Issa JP, Bast RC Jr, Yu Y. Yuan J, et al. Cancer Res. 2003 Jul 15;63(14):4174-80. Cancer Res. 2003. PMID: 12874023 - Invasion suppressor cystatin E/M (CST6): high-level cell type-specific expression in normal brain and epigenetic silencing in gliomas.
Qiu J, Ai L, Ramachandran C, Yao B, Gopalakrishnan S, Fields CR, Delmas AL, Dyer LM, Melnick SJ, Yachnis AT, Schwartz PH, Fine HA, Brown KD, Robertson KD. Qiu J, et al. Lab Invest. 2008 Sep;88(9):910-25. doi: 10.1038/labinvest.2008.66. Epub 2008 Jul 7. Lab Invest. 2008. PMID: 18607344 Free PMC article. - Stem cell chromatin patterns: an instructive mechanism for DNA hypermethylation?
Ohm JE, Baylin SB. Ohm JE, et al. Cell Cycle. 2007 May 2;6(9):1040-3. doi: 10.4161/cc.6.9.4210. Epub 2007 May 28. Cell Cycle. 2007. PMID: 17457052 Free PMC article. Review.
Cited by
- Cystatins in immune system.
Magister S, Kos J. Magister S, et al. J Cancer. 2013;4(1):45-56. doi: 10.7150/jca.5044. Epub 2012 Dec 20. J Cancer. 2013. PMID: 23386904 Free PMC article. - CST6 protein and peptides inhibit breast cancer bone metastasis by suppressing CTSB activity and osteoclastogenesis.
Li X, Liang Y, Lian C, Peng F, Xiao Y, He Y, Ma C, Wang Y, Zhang P, Deng Y, Su Y, Luo C, Kong X, Yang Q, Liu T, Hu G. Li X, et al. Theranostics. 2021 Oct 11;11(20):9821-9832. doi: 10.7150/thno.62187. eCollection 2021. Theranostics. 2021. PMID: 34815788 Free PMC article. - Cytotoxicity Effects of Amoora rohituka and chittagonga on Breast and Pancreatic Cancer Cells.
Chan LL, George S, Ahmad I, Gosangari SL, Abbasi A, Cunningham BT, Watkin KL. Chan LL, et al. Evid Based Complement Alternat Med. 2011;2011:860605. doi: 10.1155/2011/860605. Epub 2011 Apr 26. Evid Based Complement Alternat Med. 2011. PMID: 21584193 Free PMC article. - Cystatin E/M suppresses legumain activity and invasion of human melanoma.
Briggs JJ, Haugen MH, Johansen HT, Riker AI, Abrahamson M, Fodstad Ø, Maelandsmo GM, Solberg R. Briggs JJ, et al. BMC Cancer. 2010 Jan 15;10:17. doi: 10.1186/1471-2407-10-17. BMC Cancer. 2010. PMID: 20074384 Free PMC article. - DNMT3b overexpression contributes to a hypermethylator phenotype in human breast cancer cell lines.
Roll JD, Rivenbark AG, Jones WD, Coleman WB. Roll JD, et al. Mol Cancer. 2008 Jan 25;7:15. doi: 10.1186/1476-4598-7-15. Mol Cancer. 2008. PMID: 18221536 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous